Introduction
MOTION SICKNESS, SECONDARY, MOTION SICKNESS
Several questionnaires have been developed to assess motion sickness [The Motion Sickness Severity Scale (MSSS), previously used in an efficacy study of Hyoscine (Scopolamine) [Similarly, the 11-point Motion Illness Symptoms Classification (MISC) scale, which was also developed to assess motion sickness symptomatology during stimulus presentation, has been employed prior to its performance evaluation [Therefore, in this secondary analysis of data from a clinical efficacy study (Motion Sifnos) for the development of Tradipitant (a novel neurokinin-1 antagonist) for the treatment of motion sickness [